About
Consulting in the fields of:
Biotech opportunity analysis for investment of unlisted and listed life sciences.
Biopharmaceuticals, vaccines and delivery technologies for Human and Animal Health.
Strengths: Taking R&D projects from discovery phase to market in vaccines (4 products), biopharma and diagnostics (2 products) with a track record in innovation, team and project leadership and DELIVERING.
I have 35 years broad experience in leading and managing R&D stages, plus scale-up transfer to manufacturing and global tech-transfer. 4 products launched to global markets demonstrates an ability to lead and enthuse project teams to deliver commercial goals.
Management experience leading and motivating R&D teams in both academic and commercial settings, resulting in multiple patents and first to market innovative products.
Over 20 years experience in new opportunity evaluation and IP strategy with 5 years in investment analysis of small and micro cap biotechs.
Expertise in:
Scientific and commercial/investment evaluation of new technologies and product opportunities.
Strategic planning for new opportunity adoption
R&D Portfolio planning.
Vaccines: formulation, immunomodulator / adjuvant selection, delivery technologies
Biopharma approaches for non-infectious targets.
Peptide vaccines
Delivery/slow release of biologicals
Activity
-
Great to see former colleague Debbie Drane sharing the CSL story at MTPConnect's #BIO2024 event on a delightful sunny evening at the Hotel del…
Great to see former colleague Debbie Drane sharing the CSL story at MTPConnect's #BIO2024 event on a delightful sunny evening at the Hotel del…
Liked by John Walker
-
New research solves 80-year mystery: Researchers, led by Prof Tim Stinear at the Doherty Institute, have cracked the code unveiling mosquitoes as the…
New research solves 80-year mystery: Researchers, led by Prof Tim Stinear at the Doherty Institute, have cracked the code unveiling mosquitoes as the…
Liked by John Walker
-
Today, Brandon Capital portfolio company Aravax announced a $42 million USD Series B funding round. Led by our Partner Chris Smith, the round…
Today, Brandon Capital portfolio company Aravax announced a $42 million USD Series B funding round. Led by our Partner Chris Smith, the round…
Liked by John Walker
Experience
-
JW Consulting Aust Pty Ltd
-
-
-
-
-
-
-
-
Education
More activity by John
-
I’m happy to share that I’m Retired! Grandparenthood is splendid.
I’m happy to share that I’m Retired! Grandparenthood is splendid.
Liked by John Walker
-
The Lancet Infectious Diseases has published phase 3 result for ARCT-154, CSL and Arcturus Therapeutics’ novel self-amplifying mRNA vaccine. The…
The Lancet Infectious Diseases has published phase 3 result for ARCT-154, CSL and Arcturus Therapeutics’ novel self-amplifying mRNA vaccine. The…
Liked by John Walker
-
A delight to see our former director Sir Gustav Nossal immortalised in bronze! Nossal High School has proudly unveiled a life-sized statue of the…
A delight to see our former director Sir Gustav Nossal immortalised in bronze! Nossal High School has proudly unveiled a life-sized statue of the…
Liked by John Walker
-
I’ve just started as CSIRO’s Chief Executive and what a special place this is – a national science agency committed to delivering the very best…
I’ve just started as CSIRO’s Chief Executive and what a special place this is – a national science agency committed to delivering the very best…
Liked by John Walker
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named John Walker in Australia
300 others named John Walker in Australia are on LinkedIn
See others named John Walker